US 12,263,145 B2
Methods of administering solriamfetol to lactating women
Herriot Tabuteau, New York, NY (US)
Assigned to AXSOME MALTA LTD., Qormi (MT)
Filed by AXSOME MALTA LTD., Qormi (MT)
Filed on Oct. 25, 2024, as Appl. No. 18/926,907.
Application 18/926,907 is a continuation of application No. 18/819,015, filed on Aug. 29, 2024.
Application 18/819,015 is a continuation of application No. 18/491,319, filed on Oct. 20, 2023, granted, now 12,102,609.
Application 18/491,319 is a continuation in part of application No. 18/176,855, filed on Mar. 1, 2023, granted, now 11,793,776.
Application 18/176,855 is a continuation of application No. 18/148,682, filed on Dec. 30, 2022, granted, now 11,771,666.
Prior Publication US 2025/0041251 A1, Feb. 6, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/165 (2006.01)
CPC A61K 31/165 (2013.01) 26 Claims
 
1. A method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a human subject treated with solriamfetol comprising:
administering solriamfetol orally at a once-daily dose of about 75 mg to the subject; and
feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject,
and the cumulative amount of solriamfetol excreted in breast milk over 8 hours is about 0.26 mg or lower.